TOP TEN perturbations for 38809_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38809_s_at
Selected probe(set): 209202_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38809_s_at (209202_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)
Relative Expression (log2-ratio):1.5392666Number of Samples:20 / 19
| Experimental | atopic dermatitis study 12 (non-lesional; adults) |
| Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | atopic dermatitis study 12 (non-lesional; children) |
| Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)
Relative Expression (log2-ratio):1.4306107Number of Samples:20 / 18
| Experimental | atopic dermatitis study 12 (lesional; adults) |
| Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | atopic dermatitis study 12 (lesional; children) |
| Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
breast cancer study 42 (metastase; lymph node) / breast cancer study 42 (metastase; chest wall)
Relative Expression (log2-ratio):1.2246113Number of Samples:7 / 2
| Experimental | breast cancer study 42 (metastase; lymph node) |
| Metastatic tumor tissue obtained from the lymph node of patients with primary breast adenocarcinoma. | |
| Control | breast cancer study 42 (metastase; chest wall) |
| Metastatic tumor tissue obtained from the chest wall of patients with primary breast adenocarcinoma. |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)
Relative Expression (log2-ratio):-1.212451Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (confluent) |
| Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert. |
HIF-1a depletion study 1 (siRNA) / deferoxamine study 5
Relative Expression (log2-ratio):1.1548615Number of Samples:3 / 3
| Experimental | HIF-1a depletion study 1 (siRNA) |
| siRNA against HIF-1a treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). | |
| Control | deferoxamine study 5 |
| Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)
Relative Expression (log2-ratio):-1.1402807Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (subconfluent) |
| Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Relative Expression (log2-ratio):-1.067359Number of Samples:6 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). |
expO stomach cancer study 1 (gastrointestinal stromal tumor; primary) / expO stomach cancer study 1 (Signet ring cell carcinoma; primary)
Relative Expression (log2-ratio):1.0430927Number of Samples:2 / 2
| Experimental | expO stomach cancer study 1 (gastrointestinal stromal tumor; primary) |
| Primary tumor tissue samples obtained from the stomach of patients with gastrointestinal stromal tumor. | |
| Control | expO stomach cancer study 1 (Signet ring cell carcinoma; primary) |
| Primary tumor tissue samples obtained from the stomach of patients with Signet ring cell carcinoma. |
expO stomach cancer study 1 (gastrointestinal stromal tumor; primary) / expO stomach cancer study 1 (adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):1.0117531Number of Samples:2 / 3
| Experimental | expO stomach cancer study 1 (gastrointestinal stromal tumor; primary) |
| Primary tumor tissue samples obtained from the stomach of patients with gastrointestinal stromal tumor. | |
| Control | expO stomach cancer study 1 (adenocarcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the stomach of patients with adenocarcinoma (NOS). |
diabetes type 1 study 7 / normal blood sample
Relative Expression (log2-ratio):-1.0032444Number of Samples:3 / 16
| Experimental | diabetes type 1 study 7 |
| Whole blood samples from longitudinal study of children presenting with type 1 diabetes (T1D) -associated autoantibodies, who were classified with T1D at this point; T1D present at first-degree relatives. | |
| Control | normal blood sample |
| Whole blood sample from children persistently negative for type 1 diabetes autoantibodies. The subjects were matched for gender, age and HLA-genotype. |